Prostate cancer risk stratification based on conventional clinical and pathologic characteristics alone may misclassify a proportion of men at various stages of the disease process. Many gene-based assays have emerged in recent years that seek to improve the predictive accuracy in the prediagnostic and postdiagnostic settings.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Following primary treatment failure, gene expression tests may offer improved stratification of individuals at risk for disease progression and inform refinements in the necessity of additional treatment. Unifying limitations among all novel gene-based tests are include clinical validation derived from historical cohorts and a dearth of empirical clinical effectiveness data.
The Urologic clinics of North America. 2015 Oct 31 [Epub]
Michael S Leapman, Peter R Carroll
Department of Urology, UCSF - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. , Department of Urology, UCSF - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.